课题基金 / 基金详情

项目摘要

项目成果

LINDA A. SCHULER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):75%的女性乳腺肿瘤表达雌激素受体α(ER?+)。虽然抗雌激素药物显著降低了许多患有这种“管腔”肿瘤亚型的妇女的死亡率,但这些患者中有四分之一最终死于抗雌激素耐药癌症。肿瘤起始细胞或“癌症干细胞”已经涉及对常规疗法的抗性、复发和转移。然而,腔肿瘤的起源和细胞的特性,抗拒治疗仍然未知。ER?+小鼠模型有助于这些研究的乳腺癌非常罕见。多项研究指出催乳素(PRL)与ER+的发病机制和治疗反应之间存在密切联系。乳腺癌我们的体内模型,NRL-PRL转基因小鼠,允许解剖的动态过程,导致不同的癌症与转录谱,类似于腔肿瘤亚型的妇女,包括ER?表情 在这个新的应用中,我们将采用这个模型来研究PRL与卵巢类固醇合作调节乳腺上皮祖细胞和肿瘤细胞亚群,促进管腔癌发展的假设。此外,这些肿瘤含有肿瘤起始细胞,其显示出与大部分肿瘤细胞不同的激素依赖性和治疗敏感性。在目的1中,我们将建立PRL和串扰与卵巢类固醇对乳腺上皮细胞亚群的nonparous女性病变前,由表面标志物和功能祖细胞测定,并确定这些过程中的关键介质。在目的2中,我们将确定PRL诱导的ER+中肿瘤起始细胞的特征。癌,并确定其对PRL和卵巢类固醇的依赖性和对辅助治疗的敏感性。在目标3中,我们将阐明PRL和一个特征明确的致癌信号之间的相互作用,连环蛋白在正常乳腺亚群和肿瘤亚型的调节中,通过检查病变前、早期病变和癌中串扰对上皮亚群的净效应。 这些研究将阐明PRL与内源性类固醇和癌基因相互作用以促进管腔型乳腺癌亚型的机制及其在治疗敏感性中的作用。他们将在PRL诱导的ER?+中检验癌症干细胞假说。癌,产生一个新的和生物学相关的范例,了解这种流行的肿瘤亚型,使设计新的治疗方法。 公共卫生相关性:尽管抗雌激素药物显著降低了许多“管腔”ER+型乳腺癌患者的死亡率,但这些患者中有四分之一最终死于这些肿瘤。“癌症干细胞”与对常规疗法的抗性、复发和转移有关。然而,腔肿瘤的起源和细胞的特性,抗拒治疗仍然未知。我们将使用ER+乳腺癌的小鼠模型来阐明促进这种乳腺癌亚型的癌基因相互作用,并测试ER+癌中的癌症干细胞假说。这些研究将产生一个新的和生物学相关的范例,以了解这种流行的肿瘤亚型,并使新的治疗方法的设计成为可能。
英文摘要
DESCRIPTION (provided by applicant): 75% of all breast tumors in women express estrogen receptor alpha (ER?+). Although anti-estrogens have markedly reduced mortality for many women with this "luminal" tumor subtype, one quarter of these patients eventually succumb to anti-estrogen-resistant cancer. Tumor initiating cells, or "cancer stem cells" have been implicated in resistance to conventional therapies, recurrence and metastasis. However, the origin of luminal tumors and the characteristics of the cells that defy treatment remain unknown. Mouse models of ER?+ breast cancer that would facilitate these studies are very rare. Multiple studies point to a close link between prolactin (PRL), aand the pathogenesis and therapeutic responsiveness of ER?+ breast cancer. Our in vivo model, the NRL-PRL transgenic mouse, permits dissection of the dynamic processes that lead to diverse carcinomas with transcript profiles that resemble the luminal tumor subtype in women, including ER? expression. In this new application, we will employ this model to investigate the hypothesis that PRL cooperates with ovarian steroids to modulate mammary epithelial progenitor and tumor cell subpopulations, promoting the development of luminal carcinomas. Further, these tumors contain tumor initiating cells, which display hormonal dependencies and therapeutic susceptibilities distinct from the bulk of tumor cells. In Aim 1, we will establish the effect of PRL and crosstalk with ovarian steroids on mammary epithelial subpopulations in nonparous females prior to lesions, as defined by surface markers and functional progenitor assays, and identifies key mediators of these processes. In Aim 2, we will determine characteristics of tumor initiating cells in PRL-induced ER?+ carcinomas, and ascertain their dependence on PRL and ovarian steroids and susceptibility to adjuvant treatment. In Aim 3, we will elucidate interplay between PRL and a well-characterized oncogenic signal, ?-catenin, in regulation of normal mammary subpopulations and tumor subtype by examining the net effect of crosstalk on epithelial subpopulations prior to lesions, in early lesions, and carcinomas. These studies will illuminate the mechanism(s) whereby PRL interacts with endogenous steroids and oncogenes to promote the luminal breast cancer subtype, and its role in treatment sensitivity. They will test the cancer stem cell hypothesis in PRL-induced ER?+ carcinomas, generating a new and biologically relevant paradigm for understanding this prevalent tumor subtype, enabling the design of novel therapeutic approaches. PUBLIC HEALTH RELEVANCE: Although anti-estrogens have markedly reduced mortality for many women with the "luminal" ER+ type of breast cancer, one quarter of these patients eventually succumb to these tumors. "Cancer stem cells" have been implicated in resistance to conventional therapies, recurrence and metastasis. However, the origin of luminal tumors and the characteristics of the cells that defy treatment remain unknown. We will use a mouse model of ER+ breast cancer to elucidate hormone-oncogene interactions which promote this breast cancer subtype, and to test the cancer stem cell hypothesis in ER+ carcinomas. These studies will generate a new and biologically relevant paradigm for understanding this prevalent tumor subtype, and enable the design of novel therapeutic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Matrix density promotes pro-tumorigenc hormone actions in breast cancer
  • 批准号:
    9228974
  • 项目类别:
  • 资助金额:
    $46.52万
  • 财政年份:
    2014
  • 负责人:
    LINDA A. SCHULER
  • 依托单位:
Matrix density promotes pro-tumorigenc hormone actions in breast cancer
  • 批准号:
    9379069
  • 项目类别:
  • 资助金额:
    $6.24万
  • 财政年份:
    2014
  • 负责人:
    LINDA A. SCHULER
  • 依托单位:
Prolactin: mammary progenitors and tumor initiating cells in luminal carcinomas
  • 批准号:
    8677796
  • 项目类别:
  • 资助金额:
    $29.89万
  • 财政年份:
    2011
  • 负责人:
    LINDA A. SCHULER
  • 依托单位:
Prolactin: mammary progenitors and tumor initiating cells in luminal carcinomas
  • 批准号:
    8298139
  • 项目类别:
  • 资助金额:
    $30.81万
  • 财政年份:
    2011
  • 负责人:
    LINDA A. SCHULER
  • 依托单位:
海外基金